Chapter 32: Antimycobacterial Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when you think about a bacterial infection, you expect this like really quick, decisive victory.

Right.

Yeah.

A few days of treatment and you're done.

Exactly.

You get strep throat.

Your doctor prescribes a standard antibiotic like amoxicillin and the bacteria are wiped out rapidly.

You just move on with your week.

It's fast, efficient,

and highly predictable.

We are so used to that fast acting pharmacology.

I mean, most pathogens we encounter multiply quickly.

So they die just as quickly when you hit them with the right chemical.

But then you step into the world of mycobacterial infections, pathogens like the one that causes tuberculosis.

And suddenly that entire expectation just completely shatters.

Oh, absolutely.

It flips the whole paradigm.

You are no longer fighting a quick skirmish.

You're settling in for a protracted siege.

Yeah.

You're looking at a treatment landscape that requires massive coordinated chemical artillery over months, sometimes even years, just to cure a single infection.

It's intense.

It really is.

So welcome to a very special last minute lecture edition of our deep dive.

Our mission today is singular, and it's tailored specifically for you, the listener.

We are going to completely master the pharmacology of antimicrobacterial drugs from Chapter 32.

We've got a lot of ground to cover.

We're taking textbook material, clinical guidelines, pharmacological pathways,

and translating it all into an engaging story.

Just in time for your upcoming pharmacology exam or Chronicle Rotation, we are sticking strictly to the text, but making it make sense.

Exactly.

And we're going to build this conceptually from the ground up.

So we'll start by decoding the unique and frankly really stubborn biology of these bacteria.

Because once you understand how they're built, the clinical strategies actually make total sense.

Right.

And from there, we'll systematically break down the first line and second line drugs for TB and then leprosy.

We'll detail how they work, how they're metabolized, and the critical side effects you absolutely have to monitor.

OK.

Let's untack this.

I want to start with the enemy itself, mycobacteria.

What exactly makes them so vastly different from the standard bacteria that cause a sinus infection?

Physiologically, mycobacteria are aerobic rod -shaped bacilli,

but the single most important thing to understand about them is their speed, or rather their absolute lack of it.

They're slow.

Incredibly slow.

In a lab setting, they only divide every 18 to 24 hours.

Wait, 18 to 24 hours just to divide once?

Yeah.

It's wild when you compare it to something like E.

coli, which can divide every 20 minutes.

So while a normal bacterial population explodes overnight, these guys are playing a really long game.

Exactly.

And that slow growth is directly tied to their primary defense mechanism.

If you picture a normal bacterium wearing a light cotton t -shirt, a mycobacterium is walking around in a thick, dense, waxy coat of armor.

A waxy coat?

What is that armor actually made of?

It's constructed out of mycolic acids.

These are very long -chain beta -hydroxylated fatty acids.

Got it.

Because of this highly lipophilic, fat -loving cell wall, they are essentially waterproof.

If a lab tech tries to use a standard Gram stain on them, the dye just slides right off.

So how do we even identify them under a microscope if standard stains don't work?

Well, the lab has to use heat and specialized techniques to force the stain through that waxy layer.

But here's the fascinating part.

Okay.

Once that dye is finally inside,

they hold onto it so stubbornly that even washing them with harsh, acidified organic solvents won't remove the color.

Wow.

Yeah.

This unique trait earned them the famous clinical title,

acid -fast bacilli.

Acid -fast.

Right.

So that waxy armor doesn't just block lab stains.

It blocks standard antibiotics and it blocks our own immune system.

And the clinical result of that is severe.

These infections classically cause slow -growing granulomatous lesions that cause massive tissue destruction over time.

And mycobacterium tuberculosis is the main villain here, right?

It can cause latent infection where you're infected but have no symptoms or active TB, which is the leading infectious cause of death worldwide.

It is.

But we also have to keep an eye on non -tuberculous mycobacteria or NTMs, things like mycobacterium avium intracellular, which frequently affect immunocompromised patients.

Right.

The chapter mentions those.

And finally, there's mycobacterium leprae, which is the pathogen responsible for leprosy.

Okay.

So if these bacteria grow so agonizingly slowly and they wear this impenetrable waxy armor, how do we actually treat them?

I'm assuming we can't just throw a standard single antibiotic at them and hope for the best.

If you attempt to use a single standard antibiotic, you are guaranteeing failure, period.

Guaranteed.

Historically, when doctors first discovered the drug streptomycin, they thought they had a cure for TB.

So they gave it as a monotherapy.

And let me guess, the bacteria adapted.

Drastically.

There's a graph in the chapter, figure 32 .2, that shows this perfectly.

If you track the days after initiation of treatment against the resistance percentage within a matter of weeks of starting monotherapy,

the percentage of resistant bacteria in the patient's sputum skyrockets to nearly 100%.

Oh, wow.

You see,

populations of m -tuberculosis naturally contain small numbers of mutant organisms that are inherently resistant to any particular drug.

So under the selective pressure of just one drug,

all the susceptible bacteria die, leaving all the resources for the resistant ones.

Exactly.

They multiply and suddenly the entire population is immune to your treatment.

So using one drug is like sending a single soldier against a fortress.

The bacteria figure out how to beat it and soon the whole population is immune to your attack.

So we have to overwhelm them.

We do.

Active disease always requires treatment with a multi -drug regimen.

We hit them from multiple angles simultaneously.

So that if a mutant survives one drug, the other drugs immediately wipe it out.

Exactly.

And the standard treatment schedule in figure 32 .3 reflects that intensity.

Right, the short course chemotherapy schedule.

Yes.

You start with an intensive phase that lasts for two full months.

During this phase, you hit the bacteria with four different drugs all at once.

Isoniazid, rifampin, perizinimide, and ethambutol.

Four drugs for two months.

That's intense.

It is.

Then, assuming the bacterial load is drastically dropped, you drop two of the drugs and enter the continuation phase.

For the next four months, the patient takes just isoniazid and rifampin.

But we have to think about the human element here, right?

Taking a handful of highly toxic drugs every single day for half a year or up to two years for resistant strains is exhausting.

It makes patients feel terrible.

So naturally, patient adherence severely drops off.

And the moment they stop taking their meds or just start skipping days, that resistance curve shoots right back up.

Precisely.

That's why public health departments rely on DOT, or Directly Observed Therapy.

Healthcare workers literally sit with the patients and physically watch them swallow their medication.

It sounds kind of invasive.

It does, but it is clinically necessary.

It drastically decreases drug resistance and improves overall cure rates across the entire population.

Here's where it gets really interesting.

I want to pivot from the overarching strategy to the specific weapons.

Let's talk about the heavy hitters of that intensive phase, starting with the biggest one.

Isoniazid, commonly abbreviated as INH.

Isoniazid is arguably the most important TB drug in our arsenal.

And its mechanism is brilliant.

It's essentially a molecular Trojan horse.

Meaning the drug itself isn't toxic when you swallow it.

Exactly.

Isoniazid is a prodrug.

In its original form, it is completely inactive.

It floats around harmlessly, crosses into the mycobacterium, and does nothing.

Until something triggers it.

Right.

The bacteria's own enzyme, specifically a catalase peroxidase called CACHE, interacts with it.

The bacteria's own metabolism accidentally activates the drug.

They literally arm the bomb that destroys them.

That is incredible.

They do that to themselves.

And once that bomb is armed by CACHE, what is the actual target?

Once activated, Isoniazid specifically targets two mycobacterial enzymes.

In HESI and CASA.

These two enzymes are the factory workers responsible for synthesizing mycolic acid.

Ah.

So INH shuts down the armor factory?

Exactly.

Without mycolic acid, the cell wall breaks apart and the bacteria die.

And logically, this explains how resistance happens.

If a mutant bacterium simply deletes or alters its CACHE enzyme, it loses the ability to activate the prodrug.

Yep.

The Trojan horse never opens, rendering INH completely useless.

That's the exact mechanism of resistance.

Now, how the human body processes INH is just as fascinating.

INH is metabolized in the liver through a process called N -acetylation.

Okay.

But human genetics play a massive role here.

If you look at figures 32 .4 and 32 .5, they show a bimodal distribution for INH half -lives.

The way we acetylate this drug isn't uniform.

So you basically have two completely different camps of people.

You have rapid acetylators who metabolize and clear the drug quickly, giving it a half -life of about one hour.

And then you have second distinct group, the slow acetylators, who process it much slower, resulting in a half -life closer to three hours.

Does being a slow or fast acetylator change the side effects?

Because we need to talk about the collateral damage here.

What happens to the human body on this drug?

The side effect profile can be really intense.

The most serious adverse effect is hepatitis liver inflammation.

Which can be fatal, right?

It can be, if it's unrecognized.

And the risk increases significantly if the patient is over 35 or if they drink alcohol daily.

I also see a major warning in the text about peripheral neuropathy.

Patients complain of a pins and needles sensation or even numbness in their hands and feet.

Why does an antibacterial drug cause nerve damage?

That comes down to a structural quirk.

Isoniazid promotes the excretion of pyridoxin, which is vitamin B6.

It essentially strips the body of B6.

And we need that for our nerves.

Desperately.

Our nervous system needs B6 to synthesize neurotransmitters and maintain healthy nerves.

So when INH causes a relative B6 deficiency, the nerves start misfiring, causing that neuropathy.

So how do you fix that?

Do you just stop the TB treatment entirely?

No, you don't have to stop it.

You simply co -administer a daily vitamin B6 supplement alongside the isoniazid.

It completely prevents neuropathy without interfering with the antibiotic effect.

That's a surprisingly elegant solution.

But we also have to worry about drug interactions.

The pharmacology notes highlight that isoniazid interacts heavily with the liver's cytochrome P450 enzymes, as shown in figure 32 .6.

Yes.

The cytochrome P450 system is the liver's primary chemical breakdown facility.

Isoniazid acts as a competitive inhibitor of these enzymes.

It basically places a giant stop sign on them.

It hogs all the machinery.

So if INH is hogging the breakdown machinery, any other drugs the patient is taking can't get processed.

They just pile up in the bloodstream.

Exactly.

If a patient is taking phenytoin or carbamazepine for seizures, INH prevents the liver from clearing those seizure meds.

They build up to highly toxic levels.

Which causes what, exactly?

It can cause nystagmus, which is involuntary, rapid darting of the eyes,

or ataxia, which is a severe loss of physical coordination and balance, even seizures.

That is a critical monitoring point.

Okay, if INH is the Trojan horse stopping the armor production, what's our second essential weapon, rifampin, doing?

Rifampin takes a completely different but equally lethal approach.

It targets the bacteria's genetic blueprint reading process.

Specifically, it blocks RNA transcription by interacting with the beta subunit of mycobacterial DNA -dependent RNA polymerase.

Wait, let me make sure I have the cellular biology right.

RNA polymerase is the enzyme that reads the DNA code and creates RNA, which the bacteria use to build proteins.

Correct.

So if rifampin jams that enzyme, the bacteria can't read their own blueprints.

They can't make any proteins and they die.

That is exactly right.

It works on both extracellular and intracellular mycobacteria.

But its pharmacokinetics come with a massive, highly testable warning.

I know exactly what you're going to say.

The chart in figure 32 .7 shows its elimination through bile and urine.

But the big warning is the color change.

Rifampin has a very distinct bright reddish orange color.

It will turn a patient's urine, feces, saliva, sweat, and even their tears, bright orange red.

You absolutely have to warn patients about this in advance.

If you don't, they will wake up, see bright red urine, think they are hemorrhaging internally, and rush to the emergency room in an absolute panic.

Oh, for sure.

And the text specifically mentions it can permanently ruin soft contact lenses by staining them orange.

It's a huge cosmetic shock.

But functionally, rifampin also has a unique pharmacokinetic quirk called autoinduction.

Autoinduction.

Meaning it induces its own metabolism.

Yes.

Over the first week or two of dosing, rifampin actually stimulates the liver to produce more of the enzymes that break it down.

It effectively teaches the liver how to destroy it faster, so its half -life actually shortens the longer you take it.

But wait.

Earlier we said INH places a stop sign on the liver enzymes and slows down the metabolism of other drugs.

Does rifampin do the opposite?

It does the exact opposite.

Rifampin puts a fast -forward symbol on the P450 liver enzymes.

It is one of the most potent inducers of the cytochrome P450 system in all of pharmacology.

It forces the liver into overdrive.

So if the liver is in overdrive, it's going to chew through any other medications the patient is taking way too fast.

Precisely.

It drastically decreases the half -lives of co -administered drugs.

It will clear out oral contraceptives rendering them ineffective.

It will clear out warfarin, destroying its blood thinning effects.

And most critically, it will clear out HIV protease inhibitors.

That brings up a huge clinical dilemma.

HIV and tuberculosis frequently co -infect patients.

Very frequently.

So if your TB patient desperately needs those protease inhibitors to keep their HIV in check, you can't just give them rifampin and wash all their life -saving HIV meds out of their system?

No.

What do you do?

Are there relatives of rifampin we can use?

Yes.

You swap to a relative called rifibutin.

Rifibutin works the same way against the bacteria, but it is a much less potent P450 inducer.

It's about 40 % less potent.

OK.

So that's the preferred agent for TB patients co -infected with HIV.

Exactly.

Though it does have its own specific adverse effects to monitor, like uveitis, which is inflammation of the eye, and hyperpigmentation of the skin.

And what about rifapentine?

The text mentions that one, too.

Right.

Rifapentine has a much longer half -life, so it's mainly used once weekly for latent TB infections.

OK.

Moving back to standard active TB, we still have two more drugs from that initial four -drug intensive phase to cover, parazinamide and ethambutol.

Parazinamide is fascinating because its exact mechanism of action is still somewhat of a pharmacological mystery.

Like INH, it's a prodrug.

It requires a bacterial enzyme, parazinatidase, to become the active molecule, parazinoic acid.

If the mechanism is a mystery, why do we use it?

Because of where it works.

Tuberculosis bacteria love to hide out in highly acidic environments, like inside the necrotic core of a lung lesion, or even inside the lysosomes of our own macrophage immune cells.

Right.

Most drugs fail in high acid.

Parazinamide thrives in it.

It acts specifically against those hiding dormant bacilli, but its clinical benefit peaks very early on.

That's why it's usually dropped from the regimen after the first two months.

What's the major side effect we need to look out for with parazinamide?

Uric acid retention.

It prevents the kidneys from excreting uric acid properly, leading to hyperuricemia in the blood.

Look out.

Yes.

In susceptible patients, those uric acid crystals can precipitate in the joints, causing a sudden excruciating gout attack.

You have to monitor that.

Finally, rounding out the first line quartet, we have ethambutol.

Unlike the other three, ethambutol is bacteriostatic.

Meaning it doesn't actually kill the bacteria outright, it just halts their growth.

Correct.

It stops them from multiplying by inhibiting an enzyme called aerabinosal transferase.

This enzyme is absolutely vital for cross -linking the various layers of the mycobacterial cell wall.

Without it, the wall becomes structurally compromised, halting reproduction.

For ethambutol, there is one very specific highly memorable adverse effect to monitor.

Optic neuritis.

Yes.

You have to watch out for this.

It causes inflammation of the optic nerve, leading to a decrease in visual acuity and a very specific loss of the ability to discriminate between the colors red and green.

It is entirely dose dependent and usually reversible if caught early.

But you have to establish a baseline.

You must conduct visual acuity and color vision testing before you start the patient on this drug and continue to test them periodically.

If a patient mentions that stoplights are starting to look the same color, you have to intervene immediately.

Okay, so that is our incredibly potent first line intensive phase.

But what happens if the bacteria outsmart us?

What happens when a patient develops multidrug resistant TB, or MDR -TB?

Meaning the bacteria have mutated to be completely resistant to both INH and refampin.

What's our backup plan?

What's fascinating here is when we shift to second line drugs, we have to accept a harsh clinical reality.

These backup agents are generally less effective at killing the bacteria and significantly more toxic to the patient.

It's a difficult trade off.

Very difficult, but necessary to save their life.

Let's do a rapid fire breakdown of this backup arsenal.

Let's start with streptomycin.

Streptomycin is actually one of the oldest TB drugs.

It's an aminoglycoside antibiotic, so it mostly works against extracellular organisms.

But it's an injectable agent, and like all aminoglycosides, it carries severe risks of kidney damage and permanent hearing loss.

Then we have capryomycin.

Capryomycin is a polypeptide.

And similar to streptomycin, it requires careful monitoring for renal toxicity, nephrotoxicity, and hearing issues, ototoxicity.

Next is cycloserine.

The mechanism here is that it disrupts D -alanine in the cell wall, right?

But the side effect profile is terrifying.

It is.

Cycloserine easily penetrates the cerebrospinal fluid.

Because it crosses the blood -brain barrier so well, it causes massive CNS toxicity.

We're talking severe anxiety, confusion, depression, and even seizures.

That is brutal.

What about aethionamide?

Aethionamide is structurally very similar to isoniazid, an INH analog.

But it causes severe gastrointestinal intolerance and major hepato toxicity, which limits its use.

We also have the fluoroquinones, specifically moxafloxacin and levofloxacin.

Right.

And tying back to a study question in the chapter, you have to warn the listener to monitor for QT interval prolongation on an ECG with these.

They can trigger dangerous cardiac arrhythmias.

And for the NTMs, the non -tuberculous mycobacteria, we use macrolides, azithromycin and clarithromycin.

Yes.

And azithromycin is usually preferred to avoid the heavy CYP interactions that come with clarithromycin.

And finally, what about the newest weapon for MDRTB, bedaquiline?

Bedaquiline is an ATP synthase inhibitor.

It jams the turbine that generates the bacteria's energy, starving them to death.

But it is a boxed warning for QT prolongation.

And crucially, it's a CYP3A4 substrate.

Oh, wait.

So if it's a substrate metabolized by the liver, you can't give it with a strong enzyme inducer like rifampin, right?

Because the rifampin would force the liver to destroy the bedaquiline before it even had a chance to work.

Exactly.

That is a perfect pharmacological connection.

You cannot give them together.

So what does this all mean?

We have this massive toxic arsenal dedicated to fighting TB.

But the chapter doesn't stop at TB.

There's one more mycobacterium we have to face.

Leprosy.

Also known as Hansen disease.

Leprosy has a really rich and devastating global history.

But if you look at figure 32 .11, it shows a massive global drop in leprosy cases since 1985.

Proving the efficacy of modern pharmacology.

Exactly.

Multi -drug therapy changed everything.

So the treatment for leprosy utilizes rifampin, which we already know blocks RNA polymerase alongside two new drugs, dapsone and clofazamine.

Let's look at dapsone first.

Dapsone is structurally related to the sulfonamides.

It inhibits folate synthesis by blocking dihydroptorate synthase.

Without folate, they can't make DNA, so it's bacteriostatic.

But there is a specific dangerous adverse effect with dapsone, hemolysis.

Right.

And this is specifically a huge risk for patients who have a genetic glucose 6 -phosphate dehydrogenase deficiency.

G6PD deficiency.

If they lack this enzyme, their red blood cells can't handle the oxidative stress from the drug, and they basically rupture.

And what about the other key leprosy drug, clofazamine?

Clofazamine is a phenazine dye.

It likely binds to DNA and generates toxic oxygen radicals.

But because it is literally a dye, it has a highly memorable visual side effect.

Patients develop a distinct pink to brownish -black discoloration of their skin.

You absolutely have to inform them of this.

But interestingly, it also has anti -inflammatory properties, which helps prevent a painful immune reaction called erythema nodosum leprosum.

Right.

Let's do a rapid synthesis of everything we've unpacked today.

Sure.

We tracked from the biology of the mycolic acid cell wall to the rationale for multi -drug regimens.

Yeah.

We explored the mechanisms and dramatic side effects of the intensive phase, INH, rifampin, paraxanamide, and ethambutol.

And then we outlined the backup artillery for MDR, TB, and leprosy.

As you take these concepts into your exams and your clinical practice, I want to leave you with a final thought.

Think about the evolutionary arms race happening in a TB lesion.

It's intense.

We administer a carefully choreographed cocktail of four different molecular weapons, each attacking a different part of the bacteria's life cycle, just to outpace a single organism's ability to mutate.

Every dose and every phase of that treatment schedule is a calculated move in an ongoing microscopic chess match.

We have to temporarily reshape the patient's entire metabolism to become an inhospitable alien planet for the infection.

Understanding that interaction between pathogen, drug, and host is the true art of pharmacology.

It really is.

Thank you for joining us for this deep dive.

From the entire last -minute lecture team, we wish you the absolute best of luck on your upcoming pharmacology exam or clinical rotation.

You've got this.